A review of the recommendations & evidence gaps reported across **NICE's Early Value Assessments for MedTech.**

Background: The National Institute for Health and Clinical Excellence (NICE) Early Value Assessment (EVA) for


digital health & medical technologies was introduced to provide a rapid assessment based upon clinical

effectiveness and value for money whilst providing guidance on what further evidence is required. This review

aimed to quantify the recommendations & evidence gaps that have been recorded across the EVA since onset.

Result 1: Recommendations Technologies Assessed Technologies Recommended 14 12 10


Result 2: Evidence Gaps



MT45

ISPOR EU

2024



EVA Number

The number of technologies assessed in each EVA ranged from 1 to 14 with a mean number of 7.1 (SD; 4.8) technologies per EVA.

The number of technologies assessed in each EVA ranged from 1 to 14 with a mean number of 7.1 (SD; 4.8) technologies per EVA. An overall total of 100 technologies have been assessed with a 41% rate of recommendation.



EVAs with the most common required areas including healthcare resource use & cost impact (79%), clinical outcomes (71%), health-related quality of life (50%) and preference, experience & usability (50%).


Across NICE's EVA's for MedTech there is a 41% rate of

early recommendation for use in the NHS with guidance

on further evidence required on all technologies.

Methods, EVA Process & Overview





Conclusion: NICE has **assessed a wide variety of digital technologies**, with the **majority not currently**

recommended for use in the NHS. By understanding and addressing the key areas where further evidence is

required may assist future digital health & medical technologies who aim to be recommended.



George Morgan¹ & Sam Bristow¹

DHT.health, North West, United Kingdom;



Overview of EVAs